Pay in 4 interest-free payments of $5.49 Learn more
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12
Access depends on local regulations in your country
Victoria Health accepts no liability for inaccuracies or misstatements about products by manufacturers or other third parties
Other weight-loss drugs are currently in development or regulatory approval stages, including: Once-daily GLP-1 pill orforglipron (Eli Lilly), which, when taken alongside a healthy diet and exercise, resulted in a 7.5% weight loss over 72 weeks on the 6mg dose, 8.4% loss with 12mg of orforglipron, and 11.2% loss with 36mg of orforglipron, as compared with 2.1% loss with placebo (funded by Eli Lilly
It can be difficult because symptoms such as fatigue, constipation, and changes in appetite can occur with both
Research also suggests there may be a link between semaglutide and thyroid cancer based on animal studies
